Published in Bone on November 24, 2004
Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer (2012) 0.80
Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved? BMJ Case Rep (2014) 0.79
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med (2004) 3.88
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology (2002) 2.49
Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab (2005) 2.05
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev (2005) 1.88
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res (2007) 1.76
Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone (2010) 1.68
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
Diagnostic delay in sternocostoclavicular hyperostosis: impact on various aspects of quality of life. Arthritis Care Res (Hoboken) (2010) 1.63
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol (2007) 1.58
Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2004) 1.42
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res (2009) 1.41
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet (2005) 1.37
Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res (2005) 1.33
Prolonged bisphosphonate release after treatment in children. N Engl J Med (2007) 1.32
Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density. J Clin Endocrinol Metab (2015) 1.22
Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein. J Biol Chem (2002) 1.21
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem (2005) 1.12
Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res (2011) 1.11
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res (2002) 1.06
Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res (2013) 1.06
Limitations of Tc99m-MIBI-SPECT imaging scans in persistent primary hyperparathyroidism. World J Surg (2011) 1.05
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom (2011) 1.00
Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone (2012) 0.93
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res (2005) 0.92
Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging (2002) 0.91
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone (2008) 0.90
Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. Eur J Endocrinol (2005) 0.89
Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone (2012) 0.86
Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Mod Pathol (2011) 0.86
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res (2002) 0.86
Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. J Rheumatol (2004) 0.86
"Diagnostic investigation of the pelvic floor": a helpful tool in the approach in patients with complaints of micturition, defecation, and/or sexual dysfunction. J Sex Med (2008) 0.84
SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn (2007) 0.84
Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene. J Clin Endocrinol Metab (2008) 0.83
Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol (Oxf) (2004) 0.83
Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol (2011) 0.82
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs (2015) 0.81
Medical treatment of hypercalcaemia. Hormones (Athens) (2009) 0.81
Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. J Bone Miner Res (2005) 0.81
Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res (2003) 0.81
The role of selective venous sampling in the management of persistent hyperparathyroidism revisited. Eur J Endocrinol (2010) 0.81
Low-energy fractures of the humeral shaft and bisphosphonate use. J Bone Miner Res (2012) 0.80
Glucocorticoids are not always deleterious for bone. J Bone Miner Res (2010) 0.80
Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res (2002) 0.79
Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. Kidney Int (2004) 0.79
Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf) (2014) 0.79
No effect of rosuvastatin in the zoledronate-induced acute-phase response. Calcif Tissue Int (2011) 0.79
Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. Osteoporos Int (2005) 0.78
The psychological burden of an initially unexplained illness: patients with sternocostoclavicular hyperostosis before and after delayed diagnosis. Health Qual Life Outcomes (2010) 0.78
Challenges and pitfalls in the management of parathyroid carcinoma: 17-year follow-up of a case and review of the literature. Horm Cancer (2010) 0.78
Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study. J Bone Miner Res (2004) 0.78
Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates. J Craniomaxillofac Surg (2010) 0.77
No recurrence of sporadic primary hyperparathyroidism when cure is established 6 months after parathyroidectomy. Eur J Endocrinol (2009) 0.77
Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone (2003) 0.76
No association between BMD and prevalent vertebral fractures in liver transplant recipients at time of screening before transplantation. J Clin Endocrinol Metab (2014) 0.76
Bone diseases: bisphosphonates in osteoporosis--beyond 5 years. Nat Rev Rheumatol (2013) 0.76
Parathyroid gland: Is parathyroidectomy safe and beneficial in the elderly? Nat Rev Endocrinol (2009) 0.75
In Memoriam: Olav Bijvoet 1928–2014. Bone (2014) 0.75
[A woman with chronic infection of the upper legs]. Ned Tijdschr Geneeskd (2014) 0.75
Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival. Cancer (2002) 0.75
[Antitumour effects of bisphosphonates in breast cancer]. Ned Tijdschr Geneeskd (2010) 0.75
Sexual care for patients receiving dialysis: a cross-sectional study identifying the role of nurses working in the dialysis department. J Adv Nurs (2017) 0.75
The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer. Prostate (2002) 0.75